Type of HPV lesion
| | | | |
Genital warts
|
5
|
(41.7%)
|
23
|
(62.2%)
|
LGSIL1
|
3
|
(25%)
|
9
|
(24.3%)
|
HGSIL2
|
4
|
(33.3%)
|
5
|
(13.5%)
|
Site of HPV lesion
| | | | |
Uterine cervix
|
8
|
(66.7%)
|
13
|
(35.1%)
|
Vulva
|
3
|
(25%)
|
13
|
(35.1%)
|
Vulva + vagina
|
-
|
-
|
7
|
(18.9%)
|
Vulva + perineal region
|
-
|
-
|
1
|
(2.7%)
|
Uterine cervix + vulva + vagina
|
1
|
(8.3%)
|
3
|
(8.1%)
|
Type of HPV Infection
| | | | |
Single
|
3
|
(25%)
|
16
|
(43.2%)
|
Double
|
2
|
(16.7%)
|
13
|
(35.1%)
|
Multiple
|
7
|
(58.3%)
|
8
|
(21.6%)
|
Type of delivery
| | | | |
Vaginal
|
8
|
(66.7%)
|
15
|
(40.5%)
|
Vaginal + forceps
|
-
|
-
|
1
|
(2.7%)
|
Cesarean section
|
4
|
(33.3%)
|
21
|
(56.8%)
|
Mean gestational age of the delivery in the placental HPV DNA positive group (39.7 ± 1.1 weeks)
| | | | |
Mean gestational age of the delivery in the placental HPV DNA negative group (39.2 ± 2.4 weeks)
| | | | |
Gestational age at the time HPV infection was diagnosed (week)
| | | | |
≥ 4 to ≤ 12
|
2
|
(16.7%)
|
17
|
(45.9%)
|
≥ 13 to ≤ 28
|
4
|
(33.3%)
|
8
|
(21.6%)
|
≥ 29 to ≤ 42
|
1
|
(8.3%)
|
6
|
(18.9%)
|
Prior to pregnancy
|
5
|
(41.7%)
|
5
|
(13.5%)
|
Mean in the placental HPV DNA positive group (10.5 ± 13.3 weeks)
| | | | |
Mean in the placental HPV DNA negative group (14.63 ± 12 weeks)
| | | | |
Time of RUPREME
3
(min)
| | | | |
≤ 360
|
11
|
(100%)
|
35
|
(92.1%)
|
≥ 361 to ≤ 720
|
-
|
-
|
1
|
(2.6%)
|
≥ 721
|
-
|
-
|
2
|
(5.3%)
|
Mean of placental HPV DNA positive group (37 ± 37 minutes)
|
-
|
-
|
-
|
-
|
Mean of placental HPV DNA negative group (106 ± 244 minutes)
|
-
|
-
|
-
|
-
|
Duration of labor (min)
| | | | |
≤ 240
|
6
|
(54.5%)
|
22
|
(57.9%)
|
≥ 241 to ≤ 360
|
2
|
(18.2%)
|
10
|
(26.3%)
|
≥ 361
|
3
|
(27.3%)
|
6
|
(15.8%)
|
Mean of placental HPV DNA positive group (236 ± 196 minutes)
|
-
|
-
|
-
|
-
|
Mean of placental HPV DNA negative group (185 ± 203 minutes)
|
-
|
-
|
-
|
-
|
HPV lesion at delivery
| | | | |
Yes
|
7
|
(58.3%)
|
19
|
(51.4%)
|
No
|
5
|
(41.7%)
|
18
|
(48.6%)
|